Myeloid Leukemia — NIH Grants & Funding

MONDO:0004643

Funding Landscape

Myeloid Leukemia has a robust NIH research funding landscape with 230 funded grants and $196.5M in total funding over the period.

230funded grants from NIH

Portfolio: $102.9MCumulative: $196.5M173 active57 completed260 PIs90 institutions

29 new grants started in the last 12 months.

By Research Theme

Basic Science

101

Translational

Clinical

Gene/Cell Therapy

Epi / Nat. History

Biomarker / Dx

Medical Device

8 additional grants classified as “Other” (multi-disciplinary, infrastructure, etc.).

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$28.0M

FY22

$34.9M

FY23

$27.7M

FY24

$86.6M

FY25

$19.2M

FY26

By Funding Mechanism

R01

113

K08

R37

F30

F31

R21

Basic Science(101)

Basic ScienceZIACompleted

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.

Hourigan, Christopher·NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

$2,779,530 (FY2023)

NIH RePORTER

Basic ScienceP01Active

Ceramide-Directed Therapeutics for Treatment of AML

CHALFANT, CHARLES et al.·UNIVERSITY OF VIRGINIA·CHARLOTTESVILLE, VA

$2,663,053 (FY2025)

NIH RePORTER

Basic ScienceR35Active

Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting

Steidl, Ulrich·ALBERT EINSTEIN COLLEGE OF MEDICINE·BRONX, NY

$1,005,807 (FY2025)

NIH RePORTER

Basic ScienceR37Active

Metabolic control of normal and malignant hematopoiesis

Intlekofer, Andrew·SLOAN-KETTERING INST CAN RESEARCH·NEW YORK, NY

$964,128 (FY2025)

NIH RePORTER

Basic ScienceU01Active

Mechanism and therapeutic implication of RNA-modification-mediated codon-biased translation in acute myeloid leukemia

Chen, Jianjun et al.·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$941,798 (FY2025)

NIH RePORTER

Basic ScienceZIACompleted

Targeting cancer neoantigens in patients with myeloid malignancies

Leko, Vid·DIVISION OF BASIC SCIENCES - NCI

$712,168 (FY2025)

NIH RePORTER

Basic ScienceR01Active

DNMT3A in Development of Hematologic Malignancies

GOODELL, MARGARET·BAYLOR COLLEGE OF MEDICINE·HOUSTON, TX

$698,400 (FY2026)

NIH RePORTER

Basic ScienceR01Active

Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms

Papapetrou, Eirini·ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI·NEW YORK, NY

$677,959 (FY2025)

NIH RePORTER

Basic ScienceR01Active

The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia

Liu, Shujun·CASE WESTERN RESERVE UNIVERSITY·CLEVELAND, OH

$635,657 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Targeting PRC1 in leukemia

Cierpicki, Tomasz·UNIVERSITY OF MICHIGAN AT ANN ARBOR·ANN ARBOR, MI

$624,980 (FY2025)

NIH RePORTER

Translational(66)

TranslationalP50Active

The Memorial Sloan Kettering Cancer Center SPORE in Leukemia

Abdel-Wahab, Omar et al.·SLOAN-KETTERING INST CAN RESEARCH·NEW YORK, NY

$2,350,964 (FY2025)

NIH RePORTER

TranslationalU54Active

Architecture and Trajectory of Acquired Resistance to Therapy in AML

DRUKER, BRIAN et al.·OREGON HEALTH & SCIENCE UNIVERSITY·PORTLAND, OR

$1,308,996 (FY2025)

NIH RePORTER

TranslationalR01Active

DLK1 as a novel target for Down syndrome myeloid leukemia

Gopalakrishnapillai, Anilkumar·NEMOURS CHILDREN'S HOSPITAL, DELAWARE·WILMINGTON, DE

$1,273,073 (FY2025)

NIH RePORTER

TranslationalU01Active

Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia

DRUKER, BRIAN et al.·OREGON HEALTH & SCIENCE UNIVERSITY·PORTLAND, OR

$1,168,038 (FY2025)

NIH RePORTER

TranslationalR44Active

Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia

Altman, Gary et al.·CAMBIUM ONCOLOGY LLC·ATLANTA, GA

$999,997 (FY2025)

NIH RePORTER

TranslationalR35Active

Therapeutic Targeting of Human AML Stem Cells

Jordan, Craig·UNIVERSITY OF COLORADO DENVER·Aurora, CO

$921,336 (FY2025)

NIH RePORTER

TranslationalR37Active

Membrane protein target for leukemia therapy

Kang, Xunlei·UNIVERSITY OF MISSOURI-COLUMBIA·COLUMBIA, MO

$855,881 (FY2025)

NIH RePORTER

TranslationalR01Active

Screening for Inhibitors of the Chromatin Reader SGF29

Deshpande, Aniruddha et al.·SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE·LA JOLLA, CA

$768,437 (FY2025)

NIH RePORTER

TranslationalR01Active

Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia

Genovese, Pietro·BOSTON CHILDREN'S HOSPITAL·BOSTON, MA

$721,888 (FY2025)

NIH RePORTER

TranslationalR01Active

Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia

VAKOC, CHRISTOPHER et al.·COLD SPRING HARBOR LABORATORY·COLD SPRING HARBOR, NY

$709,633 (FY2025)

NIH RePORTER

Clinical(24)

ClinicalR35Active

Understanding and Targeting Aberrant RNA Splicing in Leukemia

Abdel-Wahab, Omar·SLOAN-KETTERING INST CAN RESEARCH·NEW YORK, NY

$1,034,176 (FY2025)

NIH RePORTER

ClinicalR01Active

Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia

Shively, John et al.·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$738,698 (FY2026)

NIH RePORTER

ClinicalR01Active

Predicting and Monitoring for Cardiac Toxicity in Pediatric AML

Aplenc, Richard et al.·CHILDREN'S HOSP OF PHILADELPHIA·PHILADELPHIA, PA

$678,486 (FY2025)

NIH RePORTER

ClinicalR37Active

Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.

Stieglitz, Elliot·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$673,836 (FY2025)

NIH RePORTER

ClinicalR01Active

Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia

Maciejewski, Jaroslaw et al.·CLEVELAND CLINIC LERNER COM-CWRU·CLEVELAND, OH

$654,837 (FY2025)

NIH RePORTER

ClinicalR01Active

Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2

Flavell, Robert et al.·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$610,501 (FY2026)

NIH RePORTER

ClinicalR01Active

Integrated Systems Biology of Pediatric AML

Lamba, Jatinder et al.·UNIVERSITY OF FLORIDA·GAINESVILLE, FL

$596,236 (FY2026)

NIH RePORTER

ClinicalR01Active

The role of inflammation in the regulation of immune response in acute myeloid leukemia

Aifantis, Iannis et al.·NEW YORK UNIVERSITY SCHOOL OF MEDICINE·NEW YORK, NY

$573,470 (FY2025)

NIH RePORTER

ClinicalR01Active

ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA

Kentsis, Alex·SLOAN-KETTERING INST CAN RESEARCH·NEW YORK, NY

$508,054 (FY2025)

NIH RePORTER

ClinicalR01Active

The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia

Padron, Eric·H. LEE MOFFITT CANCER CTR & RES INST·TAMPA, FL

$495,033 (FY2026)

NIH RePORTER

Epi / Nat. History(10)

Epi / Nat. HistoryR01Active

The role of adverse social-biological interactions in acute myeloid leukemia disparities

Khan, Irum·NORTHWESTERN UNIVERSITY AT CHICAGO·CHICAGO, IL

$726,828 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR01Active

Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)

Eisfeld, Ann-Kathrin et al.·OHIO STATE UNIVERSITY·Columbus, OH

$652,141 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR37Active

Aging trajectories and outcomes of older adults with acute myeloid leukemia

Bhatt, Vijaya·UNIVERSITY OF NEBRASKA MEDICAL CENTER·OMAHA, NE

$515,428 (FY2025)

NIH RePORTER

Epi / Nat. HistoryU01Active

Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation

Levine, Ross et al.·JACKSON LABORATORY·BAR HARBOR, ME

$509,734 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR37Active

Deciphering pathogenesis and therapeutic vulnerabilities in germline RUNX1 mutated AML

Xiao, Wenbin·SLOAN-KETTERING INST CAN RESEARCH·NEW YORK, NY

$495,715 (FY2025)

NIH RePORTER

Epi / Nat. HistoryU01Active

The influence of proteostasis loss in aging hematopoietic stem cells on leukemia initiation

Magee, Jeffrey et al.·UNIVERSITY OF CALIFORNIA, SAN DIEGO·LA JOLLA, CA

$364,444 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR01Active

Penalized mixture cure models for identifying genomic features associated with outcome in acute myeloid leukemia

Archer, Kellie·OHIO STATE UNIVERSITY·Columbus, OH

$258,203 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR00Active

Impact of the senescent bone marrow microenvironment in AML biology

Abdul-Aziz, Amina·TEMPLE UNIV OF THE COMMONWEALTH·PHILADELPHIA, PA

$249,000 (FY2026)

NIH RePORTER

Epi / Nat. HistoryF99Active

Determinants of susceptibility to pediatric acute myeloid leukemia

Harmon, Lauren·VAN ANDEL RESEARCH INSTITUTE·GRAND RAPIDS, MI

$3,000 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR21Completed

Developing Acute Myeloid Leukemia Models with Diverse Ancestral Origins

Pardee, Timothy·WAKE FOREST UNIVERSITY HEALTH SCIENCES·WINSTON-SALEM, NC

$177,249 (FY2025)

NIH RePORTER

Gene/Cell Therapy(13)

Gene/Cell TherapyR01Active

ROLE OF RNA SEQUESTRATION IN ACUTE MYELOID LEUKEMIA

Di Stefano, Bruno·BAYLOR COLLEGE OF MEDICINE·HOUSTON, TX

$2,398,360 (FY2025)

NIH RePORTER

Gene/Cell TherapyR01Active

Targeting MicroRNAs to Eradicate Leukemia Stem Cells

KUO, YA-HUEI et al.·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$1,011,514 (FY2025)

NIH RePORTER

Gene/Cell TherapyR01Active

Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy

Walter, Roland·FRED HUTCHINSON CANCER CENTER·SEATTLE, WA

$850,173 (FY2025)

NIH RePORTER

Gene/Cell TherapyR01Active

Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia

Hui, Susanta et al.·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$715,641 (FY2025)

NIH RePORTER

Gene/Cell TherapyR01Active

Role of targeting ATPases BRG1/BRM in therapy of AML

BHALLA, KAPIL et al.·UNIVERSITY OF TX MD ANDERSON CAN CTR·HOUSTON, TX

$542,663 (FY2025)

NIH RePORTER

Gene/Cell TherapyR01Active

Novel CART Cells for Treating AML

Hua, Xianxin·UNIVERSITY OF PENNSYLVANIA·PHILADELPHIA, PA

$518,949 (FY2025)

NIH RePORTER

Gene/Cell TherapyR01Active

Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Budde, Lihua et al.·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$489,159 (FY2025)

NIH RePORTER

Gene/Cell TherapyK08Active

Multi-antigen-specific CAR T cells to treat acute myeloid leukemia

James, Scott·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$263,034 (FY2024)

NIH RePORTER

Gene/Cell TherapyF30Active

Structure-guided protein evolution to develop improved natural ligand-based chimeric antigen receptor T cell therapy against CD70 in acute myeloid leukemia

Kang, Amrik·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$42,521 (FY2025)

NIH RePORTER

Gene/Cell TherapyF31Active

Engineering best in class Acute Myeloid Leukemia (AML) CAR-T therapies by enhancing persistence and defining the immune landscape of AML

Rampersaud, Sham·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$41,944 (FY2026)

NIH RePORTER

Biomarker / Dx(7)

Biomarker / DxR44Active

Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing

Bickel, Kellie·TWINSTRAND BIOSCIENCES, INC.·SEATTLE, WA

$1,985,831 (FY2025)

NIH RePORTER

Biomarker / DxR35Active

Molecular Pathogenesis of Acute Myeloid Leukemia

Ley, Timothy·WASHINGTON UNIVERSITY·SAINT LOUIS, MO

$932,549 (FY2025)

NIH RePORTER

Biomarker / DxR01Active

Development of a Phenotype-based Predictive Analytic for Acute Myeloid Leukemia

Method, Michael et al.·VANDERBILT UNIVERSITY MEDICAL CENTER·NASHVILLE, TN

$677,289 (FY2025)

NIH RePORTER

Biomarker / DxU01Active

Targeting minimal residual disease in AML by using single-cell morphological and biophysical analysis with deep learning

Hemann, Michael et al.·MASSACHUSETTS INSTITUTE OF TECHNOLOGY·CAMBRIDGE, MA

$655,219 (FY2025)

NIH RePORTER

Biomarker / DxR01Active

Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia

LI, LING·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$637,252 (FY2026)

NIH RePORTER

Biomarker / DxR01Active

UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

Klco, Jeffery·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$416,325 (FY2025)

NIH RePORTER

Biomarker / DxR01Active

Investigating novel synthetic lethal epigenetic interactions in Acute Myeloid Leukemia

SHI, JUNWEI·UNIVERSITY OF PENNSYLVANIA·PHILADELPHIA, PA

$335,070 (FY2026)

NIH RePORTER

Medical Device(1)

Medical DeviceR01Active

Design of an integrated microdevice to measure malignant lipid signaling in single cells from clinical samples

Allbritton, Nancy·UNIVERSITY OF WASHINGTON·SEATTLE, WA

$671,072 (FY2025)

NIH RePORTER

Other(8)

OtherR01Active

Elucidating the critical role of Wee1 in GIST

Rink, Lori et al.·RESEARCH INST OF FOX CHASE CAN CTR·PHILADELPHIA, PA

$430,050 (FY2026)

NIH RePORTER

OtherR01Active

Defining epigenetic mechanisms in NPM1c mutant leukemia

ARMSTRONG, SCOTT·DANA-FARBER CANCER INST·BOSTON, MA

$403,607 (FY2025)

NIH RePORTER

OtherR01Active

Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias

KAUFMANN, SCOTT·MAYO CLINIC ROCHESTER·ROCHESTER, MN

$363,713 (FY2025)

NIH RePORTER

OtherR01Active

Role of HOTTIP/beta-catenin-HOXA9/PRMT1 axis in hematopoietic and leukemic stem cells

Eric, So et al.·PENNSYLVANIA STATE UNIV HERSHEY MED CTR·HERSHEY, PA

$202,540 (FY2025)

NIH RePORTER

OtherR00Active

Targeting Menin Protein Stability In AML

Cutler, Jevon·OREGON HEALTH & SCIENCE UNIVERSITY·PORTLAND, OR

$195,615 (FY2026)

NIH RePORTER

OtherP30Active

CCSG - Administrative Supplement - ECIA

ODUNSI, KUNLE·UNIVERSITY OF CHICAGO·CHICAGO, IL

$70,000 (FY2025)

NIH RePORTER

OtherF99Active

Investigating the Microenvironmental Dysregulation and Polypharmacy Impact during Acute Myeloid Leukemia in an in vitro model of the human bone marrow and in vivo models.

Sharipol, Azmeer·UNIVERSITY OF ROCHESTER·ROCHESTER, NY

$34,180 (FY2025)

NIH RePORTER

OtherK08Completed

Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia

Garcia, Jacqueline·DANA-FARBER CANCER INST·BOSTON, MA

$258,561 (FY2024)

NIH RePORTER

Adjacent Research(45 grants)

These grants mention Myeloid Leukemia as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(45)

OtherP01Active

Adult Leukemia Research Center

HILL, Geoffrey·FRED HUTCHINSON CANCER CENTER·SEATTLE, WA

$4,395,431 (FY2025)

NIH RePORTER

OtherZIDCompleted

ID-CTP Clinical Core

Pai, Sung-Yun·DIVISION OF BASIC SCIENCES - NCI

$2,869,853 (FY2025)

NIH RePORTER

OtherR01Active

Uncovering mechanisms of protection from Alzheimer's disease in CHIP using human cohorts and biosamples

Bendall, Sean et al.·STANFORD UNIVERSITY·STANFORD, CA

$1,400,625 (FY2025)

NIH RePORTER

OtherR01Active

Identifying Collaborating Factors Driving DDX41 Mutant Pathology in MDS

Bowman, Teresa·ALBERT EINSTEIN COLLEGE OF MEDICINE·BRONX, NY

$829,319 (FY2026)

NIH RePORTER

OtherR01Active

Mitigating Hematologic Adverse Events in Patients with Myeloid Malignancies: A Novel Causal Artificial Intelligence Approach

Yu, Kun-Hsing·HARVARD MEDICAL SCHOOL·BOSTON, MA

$748,104 (FY2025)

NIH RePORTER

OtherR01Active

Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia

Abdel-Wahab, Omar et al.·FRED HUTCHINSON CANCER CENTER·SEATTLE, WA

$719,414 (FY2025)

NIH RePORTER

OtherR01Active

Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation

Betts, Brian et al.·ROSWELL PARK CANCER INSTITUTE CORP·BUFFALO, NY

$711,892 (FY2025)

NIH RePORTER

OtherR01Active

A compass for those with relapsed leukemia after transplant

Furlan, Scott·FRED HUTCHINSON CANCER CENTER·SEATTLE, WA

$701,179 (FY2025)

NIH RePORTER

OtherR01Active

Mechanistic studies of E3 Ub ligase in peroxisomes and mitochondria

KARBOWSKI, MARIUSZ·UNIVERSITY OF MARYLAND BALTIMORE·BALTIMORE, MD

$686,324 (FY2025)

NIH RePORTER

OtherR01Active

RUNX1-mediated regulation of MEP fate specification

Krause, Diane·YALE UNIVERSITY·NEW HAVEN, CT

$686,113 (FY2025)

NIH RePORTER

Top Funded Institutions

SLOAN-KETTERING INST CAN RESEARCH$8.8M

NY14 grantsMillman, Scott, Xiao, Wenbin +3

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE$7.8M

CA14 grantsLI, LING, Hui, Susanta +3

WASHINGTON UNIVERSITY$6.2M

MO9 grantsMendoza-Castrejon, Jonny, Kim, Miriam +3

OREGON HEALTH & SCIENCE UNIVERSITY$4.4M

OR10 grantsYashar, William, Lind, Evan +3

BAYLOR COLLEGE OF MEDICINE$3.8M

TX6 grantsDatar, Gandhar, Kodali, Srikanth +3

UNIVERSITY OF VIRGINIA$3.1M

VA4 grantsUng, Johnson, CHALFANT, CHARLES +2

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI$3.0M

NY6 grantsFerrari de Andrade, Lucas, Ma, Sai +3

FRED HUTCHINSON CANCER CENTER$2.8M

WA6 grantsWalter, Roland, LASZLO, GEORGE +2

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE$2.8M

1 grantHourigan, Christopher

OHIO STATE UNIVERSITY$2.5M

OH8 grantsLordo, Matthew, Eisfeld, Ann-Kathrin +3

Top Principal Investigators

Ley, Timothy$4.1M

WASHINGTON UNIVERSITY·2 grants

Biomarker / DxBasic Science

Abdel-Wahab, Omar$3.9M

SLOAN-KETTERING INST CAN RESEARCH·3 grants

ClinicalTranslationalBasic Science

Tyner, Jeffrey$2.8M

OREGON HEALTH & SCIENCE UNIVERSITY·3 grants

Translational

Hourigan, Christopher$2.8M

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE·1 grant

Basic Science

CHALFANT, CHARLES$2.7M

UNIVERSITY OF VIRGINIA·1 grant

Basic Science

Loughran, Thomas$2.7M

UNIVERSITY OF VIRGINIA·1 grant

Basic Science

DRUKER, BRIAN$2.5M

OREGON HEALTH & SCIENCE UNIVERSITY·2 grants

Translational

Di Stefano, Bruno$2.4M

BAYLOR COLLEGE OF MEDICINE·1 grant

Gene/Cell Therapy

Stein, Eytan$2.4M

SLOAN-KETTERING INST CAN RESEARCH·1 grant

Translational

Aifantis, Iannis$2.2M

NEW YORK UNIVERSITY SCHOOL OF MEDICINE·4 grants

ClinicalBasic Science

Track funding opportunities for Myeloid Leukemia.

Follow this disease to be notified about new NIH grants and funding changes.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.